Core Viewpoint - The approval of the roxithromycin capsules by the National Medical Products Administration of China enhances the company's competitive position in the anti-infection sector and is expected to generate greater returns for the company and its shareholders [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation of the roxithromycin capsules (150mg) [1] - Roxithromycin capsules are a second-generation macrolide antibiotic known for their acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions [1] - The product is currently listed as a Class B drug in the National Medical Insurance Directory (2025 version) [1] Group 2: Market Position and Future Prospects - The company is the first to pass the consistency evaluation for the roxithromycin capsule formulation [1] - This approval will further help the company consolidate its advantageous position in the anti-infection field [1] - The company is committed to ongoing new product development, which is anticipated to create greater benefits for the company and its shareholders [1]
联邦制药(03933.HK)：罗红霉素胶囊通过药监局仿制药质量和疗效一致性评价